Entera Bio’s Parathyroid Hormone Therapy Shows Potential in Early Phase 2 Results
Entera Bio’s investigational parathyroid hormone compound called Oral PTH (1-34) appears to be able to increase calcium levels in patients with hypoparathyroidism, interim results from a Phase 2 trial show. It can also increase blood levels of active vitamin D and reduce phosphate levels — two other hallmarks…